Personalis Announces Renewed Clinical Laboratory Accreditation from College of American Pathologists

April 29, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Apr. 29, 2020--Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the Accreditation Committee of the College of American Pathologists (CAP) has awarded re-accreditation to the Personalis Clinical Laboratory, Menlo Park, California based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.

The Personalis Clinical Laboratory was advised of this national recognition and congratulated for the excellence of the services being provided. The Personalis Clinical Laboratory is one of more than 8,000 CAP-accredited facilities worldwide.

"As Personalis has grown to serve more customers, the quality of our Clinical Laboratory operations has remained critical to our mission. Our re-accreditation from CAP is the result of daily efforts by multiple teams, and a testament to the hard work of our Clinical Laboratory team and the entire organization," said Massimo Morra, Executive Medical & Clinical Laboratory Director and Head of Quality & Regulatory at Personalis, Inc.

"Personalis has been CAP accredited since 2014, demonstrating our continued excellence in services provided. By maintaining an exemplary track record of full compliance with CAP Standards our partners can be assured that we will continue to provide outstanding quality and service," said John West, CEO, Personalis, Inc.

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program for certification under the Clinical Laboratory Improvements Act of 1988, as amended (CLIA'88).

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine the laboratory's staff qualifications, equipment, facilities, safety program and record, and overall management.

About the College of American Pathologists

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP annual report at cap.org

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis ImmunoID NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the future availability and quality of services provided by the Personalis Clinical Laboratory and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis' filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005591/en/

Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678

Media Contact:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

Source: Personalis, Inc.